According to Biotab Nutraceuticals chief marketing officer Robert Wilhovsky, there is seasonality within sleep aids. Biotab fielded the No. 3 sleep aid Alteril in food, drug and mass (without Walmart) with dollar growth of more than 126% for the 12 weeks ended April 15, according to SymphonyIRI Group data. Drug Store News caught up with Wilhovsky to talk about how Biotab approaches the overall sleep category, and how the company helps drive its sleep aid solution through key selling periods.
DSN senior editor Michael Johnsen examines in-depth sales activity in the analgesics, digestives, VMS, cough-cold, sleep and first aid categories, highlighting new products that are transforming OTC in this multi-page report.
Sleeping remedy sales reached $446.3 million on 6.5% growth for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI. And while the products sold may help consumers sleep at night, the category still is contributing a steady flow of dollars to OTC coffers.
When Procter & Gamble line extended its NyQuil brand identity into the sleep care aisle with the launch of ZzzQuil, the company did more than raise a few eyebrows. That launch awoke an entire category.
There are more than 100 million people over the age of 50 who are responsible for at least $7.1 trillion in annual economic activity – a figure that is expected to reach well over $13.5 trillion in real terms by 2032, according to Oxford Economics.
As many as 39% of Americans feel restless when they sleep at least once or twice every week, and 27.5% feel restless at least three or four nights each week, according to a survey conducted in May by Field Agent on behalf of Drug Store News.
Pain is proving to be a significant factor when it comes to sleeping patterns of Americans, according to a new poll by the National Sleep Foundation. Those suffering with chronic pain reported an average 42 minute sleep debt, whereas Americans who have experienced acute pain within the past week report a deficit of 14 minutes.